Supporting new vaccine introduction decisions: lessons learned from the Hib Initiative experience.
The introduction of Haemophilus influenzae type b (Hib) vaccine in developing countries has suffered from a long delay. Between 2005 and 2009, a surge in Hib vaccine adoption took place, particularly among GAVI-eligible countries. Several factors contributed to the increase in Hib vaccine adoption, including support provided by the Hib Initiative, a project funded by the GAVI Alliance in 2005 to accelerate evidence-informed decisions for use of Hib vaccine. This paper reviews the strategy adopted by the Hib Initiative and the lessons learned in the process, which provide a useful model to accelerate uptake of other new vaccines.
Hajjeh
R A
RA
Division of Bacterial Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS C-25, Atlanta, GA 30333, USA. RHajjeh@cdc.gov, rfh5@cdc.gov
Privor-Dumm
L
L
Edmond
K
K
O'Loughlin
R
R
Shetty
S
S
Griffiths
U K
UK
Bear
A P
AP
Cohen
A L
AL
Chandran
A
A
Schuchat
A
A
Mulholland
E K
EK
Santosham
M
M
D016667:Bacterial Capsules / Q000008:administration & dosage*; D003906:Developing Countries; D006192:Haemophilus Infections / Q000517:prevention & control*; D018073:Haemophilus Vaccines / Q000008:administration & dosage*; D006801:Humans; D017589:Immunization Programs / Q000458:organization & administration*; D055818:Public-Private Sector Partnerships
D018073:Haemophilus Vaccines; C044237:Haemophilus influenzae type b polysaccharide vaccine